Sonoma Story

<div class='circular--portrait' style='background:#FF0000;color: #F5FFFA;font-size:4em;'>SP</div>
SNOA -- USA Stock  

USD 8.11  0.06  0.73%

Lets try to go over the odds of Sonoma Pharmaceuticals to fully recover from the current slip as its shares went up 83.85%. The entity's current daily volatility is 3.91 percent, with a beta of 0.29 and an alpha of -0.03 over DOW. As many baby boomers are still indifferent towards current volatility, it makes sense to go over Sonoma Pharmaceuticals. Why are we still confident in our projection for a recovery.
Published over a month ago
View all stories for Sonoma Pharmaceuticals | View All Stories
What does a current Sonoma Pharmaceuticals volatility slip mean for investors?
Sonoma Pharmaceuticals conducts business under Healthcare sector and is part of Drug Manufacturers?Specialty & Generic industry.
Investing in Sonoma Pharmaceuticals, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Sonoma Pharmaceuticals along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Sonoma Pharmaceuticals' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Sonoma Pharmaceuticals in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Sonoma Pharmaceuticals. Your research has to be compared to or analyzed against Sonoma Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Sonoma Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Sonoma Pharmaceuticals.

How important is Sonoma Pharmaceuticals's Liquidity

Sonoma Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Sonoma Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Sonoma Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Sonoma Pharmaceuticals's total debt and its cash.

How Sonoma utilizes its cash?

To perform a cash flow analysis of Sonoma Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Sonoma Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Sonoma Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Sonoma Pharmaceuticals Correlation with Peers

Investors in Sonoma can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Sonoma Pharmaceuticals. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Sonoma Pharmaceuticals and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Sonoma is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Sonoma for more details

Acquisition by Bruce Thornton of 27777 shares of Sonoma Pharmaceuticals subject to Rule 16b-3

Legal trades by Sonoma Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Sonoma insider trading alert for grant of stock option (right to buy) by Bruce Thornton, COO, on 13th of January 2021. This event was filed by Sonoma Pharmaceuticals In with SEC on 2021-01-13. Statement of changes in beneficial ownership - SEC Form 4. Bruce Thornton currently serves as executive vice president - international operations and sales of Sonoma Pharmaceuticals [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down

Sonoma Pharmaceuticals owns Efficiency Ratio (i.e. Sharpe Ratio) of -0.0502, which indicates the firm had -0.0502% of return per unit of risk over the last month. Macroaxis standpoint towards measuring the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Sonoma Pharmaceuticals exposes twenty-seven different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to validate Sonoma Pharmaceuticals Coefficient Of Variation of 19448.68, risk adjusted performance of 0.013, and Semi Deviation of 3.2 to confirm the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Over 3 percent rise for Sonoma Pharmaceuticals. What does it mean for investors?

Sonoma Pharmaceuticals current potential upside builds up over 6.77. Sonoma Pharmaceuticals shows above-average downside volatility for the selected time horizon. We advise investors to inspect Sonoma Pharmaceuticals further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Sonoma Pharmaceuticals future alpha.

Our Final Perspective on Sonoma Pharmaceuticals

Whereas few other entities under the drug manufacturers?specialty & generic industry are still a bit expensive, Sonoma Pharmaceuticals may offer a potential longer-term growth to investors. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to drop some or all of your Sonoma Pharmaceuticals holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Sonoma Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Sonoma Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com